Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V-01-351 + V-01-B5
- Development stage
- Unknown
- Lead developer
- Livzon Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**V-01-351 + V-01-B5** is a combination COVID-19 vaccine candidate composed of two recombinant protein subunit vaccines, V-01-351 and V-01-B5, developed by Livzon Pharmaceutical Group. These vaccines are designed as variant-adapted boosters, targeting immune evasion variants of concern (VOCs) of SARS-CoV-2. The vaccines contain major neutralizing epitopes from multiple strains, particularly Beta and Delta. They are engineered as recombinant fusion protein vaccines that enhance T-cell immunity through antigen design, including IFN-α and a pan HLA-DR-binding epitope fused to the receptor-binding domain (RBD) and dimerized with a human IgG1 Fc domain. The combination aims to induce strong neutralizing antibody responses and robust cellular immunity against existing and emerging SARS-CoV-2 variants[1][3][5].
- Brand names
- V-01-351 + V-01-B5
- Other names
- V-01-351 + V-01-B5
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on V-01-351 + V-01-B5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V-01-351 + V-01-B5.